Literature DB >> 30671595

[Acute coronary syndrome : Prevention].

U Nixdorff1, G Horstick2, A Schlitt3.   

Abstract

For life style modifications primary and secondary prevention of acute coronary syndrome (ACS) are approximately similar, even though in the postinfarction situation functional diagnostic programs have to be performed in a rehabilitative manner. All three life style pillars of fitness, nutrition and relaxation implicate prognostic significance and the efficacy is higher for secondary prevention than for primary. The pharmacotherapeutic indications for thrombocyte aggregation inhibition are connected to the presence of atherosclerosis and statin medication is already connected to cardiovascular risk factor stratification, for which scores are used. Depending on the postinfarction myocardial destruction after ACS, additional pharmacotherapies, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II receptor antagonists, beta blockers and also mineral corticoid receptor antagonists are evident. New potential for prevention is ascribed to the new oral anticoagulants (NOAC) in the context of coincidental atrial fibrillation.

Entities:  

Keywords:  Atherosclerosis; Life style; Myocardial infarction; Platelet aggregation; Risk factors

Mesh:

Substances:

Year:  2019        PMID: 30671595     DOI: 10.1007/s00059-019-4782-y

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  35 in total

1.  Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Stat Med       Date:  2008-01-30       Impact factor: 2.373

Review 2.  Beyond established and novel risk factors: lifestyle risk factors for cardiovascular disease.

Authors:  Dariush Mozaffarian; Peter W F Wilson; William B Kannel
Journal:  Circulation       Date:  2008-06-10       Impact factor: 29.690

3.  Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study.

Authors:  Mahshid Dehghan; Andrew Mente; Sumathy Rangarajan; Patrick Sheridan; Viswanathan Mohan; Romaina Iqbal; Rajeev Gupta; Scott Lear; Edelweiss Wentzel-Viljoen; Alvaro Avezum; Patricio Lopez-Jaramillo; Prem Mony; Ravi Prasad Varma; Rajesh Kumar; Jephat Chifamba; Khalid F Alhabib; Noushin Mohammadifard; Aytekin Oguz; Fernando Lanas; Dorota Rozanska; Kristina Bengtsson Bostrom; Khalid Yusoff; Lungiswa P Tsolkile; Antonio Dans; AfzalHussein Yusufali; Andres Orlandini; Paul Poirier; Rasha Khatib; Bo Hu; Li Wei; Lu Yin; Ai Deeraili; Karen Yeates; Rita Yusuf; Noorhassim Ismail; Dariush Mozaffarian; Koon Teo; Sonia S Anand; Salim Yusuf
Journal:  Lancet       Date:  2018-09-11       Impact factor: 79.321

Review 4.  Atherosclerosis--an inflammatory disease.

Authors:  R Ross
Journal:  N Engl J Med       Date:  1999-01-14       Impact factor: 91.245

5.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Authors:  Paul M Ridker; Brendan M Everett; Tom Thuren; Jean G MacFadyen; William H Chang; Christie Ballantyne; Francisco Fonseca; Jose Nicolau; Wolfgang Koenig; Stefan D Anker; John J P Kastelein; Jan H Cornel; Prem Pais; Daniel Pella; Jacques Genest; Renata Cifkova; Alberto Lorenzatti; Tamas Forster; Zhanna Kobalava; Luminita Vida-Simiti; Marcus Flather; Hiroaki Shimokawa; Hisao Ogawa; Mikael Dellborg; Paulo R F Rossi; Roland P T Troquay; Peter Libby; Robert J Glynn
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

6.  Long-term follow-up of global and regional left ventricular function by two-dimensional echocardiography after thrombolytic therapy in acute myocardial infarction.

Authors:  U Nixdorff; R Erbel; T Pop; H J Rupprecht; K J Henrichs; S Mörchen; J Meyer
Journal:  Int J Cardiol       Date:  1993-08       Impact factor: 4.164

Review 7.  From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report.

Authors:  Morteza Naghavi; Erling Falk; Harvey S Hecht; Michael J Jamieson; Sanjay Kaul; Daniel Berman; Zahi Fayad; Matthew J Budoff; John Rumberger; Tasneem Z Naqvi; Leslee J Shaw; Ole Faergeman; Jay Cohn; Raymond Bahr; Wolfgang Koenig; Jasenka Demirovic; Dan Arking; Victoria L M Herrera; Juan Badimon; James A Goldstein; Yoram Rudy; Juhani Airaksinen; Robert S Schwartz; Ward A Riley; Robert A Mendes; Pamela Douglas; Prediman K Shah
Journal:  Am J Cardiol       Date:  2006-06-12       Impact factor: 2.778

8.  2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).

Authors:  Massimo F Piepoli; Arno W Hoes; Stefan Agewall; Christian Albus; Carlos Brotons; Alberico L Catapano; Marie-Therese Cooney; Ugo Corrà; Bernard Cosyns; Christi Deaton; Ian Graham; Michael Stephen Hall; F D Richard Hobbs; Maja-Lisa Løchen; Herbert Löllgen; Pedro Marques-Vidal; Joep Perk; Eva Prescott; Josep Redon; Dimitrios J Richter; Naveed Sattar; Yvo Smulders; Monica Tiberi; H Bart van der Worp; Ineke van Dis; W M Monique Verschuren; Simone Binno
Journal:  Eur Heart J       Date:  2016-05-23       Impact factor: 29.983

9.  European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).

Authors:  Joep Perk; Guy De Backer; Helmut Gohlke; Ian Graham; Zeljko Reiner; Monique Verschuren; Christian Albus; Pascale Benlian; Gudrun Boysen; Renata Cifkova; Christi Deaton; Shah Ebrahim; Miles Fisher; Giuseppe Germano; Richard Hobbs; Arno Hoes; Sehnaz Karadeniz; Alessandro Mezzani; Eva Prescott; Lars Ryden; Martin Scherer; Mikko Syvänne; Wilma J M Scholte op Reimer; Christiaan Vrints; David Wood; Jose Luis Zamorano; Faiez Zannad
Journal:  Eur Heart J       Date:  2012-05-03       Impact factor: 29.983

10.  Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.

Authors:  J Michael Gaziano; Carlos Brotons; Rosa Coppolecchia; Claudio Cricelli; Harald Darius; Philip B Gorelick; George Howard; Thomas A Pearson; Peter M Rothwell; Luis Miguel Ruilope; Michal Tendera; Gianni Tognoni
Journal:  Lancet       Date:  2018-08-26       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.